Mechanisms and Therapy of Liver Cancer

1st Edition, Volume 149 - February 10, 2021
Imprint: Academic Press
Editors: Paul B. Fisher, Devanand Sarkar
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 4 0 3 0 - 4
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 4 0 3 1 - 1

Mechanisms and Therapy of Liver Cancer, Volume 149, presents the latest information on the incidence and mortality of liver cancer research and how it has gained significant moment… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Mechanisms and Therapy of Liver Cancer, Volume 149, presents the latest information on the incidence and mortality of liver cancer research and how it has gained significant momentum because of its direct causative association with obesity-induced fatty liver disease. The literature on liver cancer is moving fast with exciting, novel findings, providing new insights reflected in the following updated chapters: Introduction and molecular classification of HCC, Signaling Pathways in Liver Cancer, HCV and HCC, NASH and HCC, Microbiome and Metabolic Abnormalities in HCC, Systemic Therapy of Liver Cancer, Immunotherapy of Liver Cancer, and Desmoplastic Tumor Microenvironment and Intrahepatic Cholangiocarcinoma Progression: Mechanisms and Therapeutic Implications.

Cover image
Title page
Table of Contents
Copyright
Contributors
Preface
Chapter One: Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
Abstract
1: Introduction
2: Etiology and risk factors
3: Liver cancer staging
4: Molecular classification of HCC
5: Discussion
Acknowledgments
Chapter Two: Signaling pathways in hepatocellular carcinoma
Abstract
1: Introduction
2: Pathways involving growth factors
3: Pathways involved in cell differentiation and development
4: Nuclear signaling pathways
5: Emerging pathways
6: Conclusions
Acknowledgment
Conflict of interest
Chapter Three: Hepatitis C virus associated hepatocellular carcinoma
Abstract
1: Introduction
2: HCV infection and immune responses
3: Risk factors for development of HCC from chronic infection
4: HCV regulation on metabolic pathways
5: Mechanisms of HCV associated HCC
6: Biomarkers for detection of HCV associated HCC
7: Therapeutic strategies for HCV associated HCC
8: Perspectives
Acknowledgments
Chapter Four: NAFLD-related HCC
Abstract
1: The problem of NAFLD-related HCC
2: Metabolic syndrome and NAFLD in driving HCC
3: NAFLD-related HCC
4: Molecular mechanisms of NAFLD-related HCC
5: Prevention and surveillance of NAFLD-related HCC
6: Management of NAFLD-related HCC
7: Conclusions/future directions
Acknowledgment
Disclosures
Chapter Five: Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome
Abstract
1: Hepatocellular carcinoma (HCC): A heterogenous and complex liver disease
2: Gut microbiota dysbiosis as an identifier of HCC
3: HCC microenvironment favors immunosuppression: Is gut microbiota a driver of this immunologic signature?
4: Hijacking energy sources: Does gut microbiota have an influence on metabolic reprogramming in HCC?
5: Immunological and gut microbiota therapeutics for HCC
6: Summary and future perspectives
Acknowledgment
Chapter Six: Systemic therapy of liver cancer
Abstract
1: Introduction
2: Staging
3: Liver function
4: Current systemic treatment
5: Histological variants
6: Conclusion
Acknowledgment
Chapter Seven: Immunotherapy in hepatocellular cancer
Abstract
1: Introduction
2: Immune checkpoint inhibitors in hepatocellular carcinoma
3: Future directions
4: Conclusion
Chapter Eight: Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Abstract
1: Introduction
2: iCCA classification, cell origins, and molecular subtypes
3: Fibroinflammatory cholangiopathies, mechanisms, and cholangiocarcinogenesis
4: The desmoplastic reaction and iCCA progression
5: Immune milieu in iCCA
6: Challenges and clinical implications
Grant Support
Conflict of interest statement

Paul B. Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and expertise

Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Virginia, USA

Devanand Sarkar

Dr. Sarkar received his MBBS from Dhaka Medical College, Bangladesh and PhD from Nagoya University, Japan. After postdoctoral training in Columbia University, NY he joined Virginia Commonwealth University (VCU) as a faculty where he is now a Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center. Dr. Sarkar’s research focuses on identifying novel regulators of hepatocellular carcinoma (HCC), especially obesity-induced HCC, and developing targeted gene- and immunotherapy based on the accrued knowledge. Dr. Sarkar has published more than 280 papers and his research is funded by NCI, NIDDK and DOD.

Affiliations and expertise

Professor in the Department of Human and Molecular Genetics, and Associate Director of Education and Training at Massey Cancer Center, Virginia Commonwealth University (VCU)

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health